Clinical Trial Rationale

Merck & Co. (MRK) has initiated patient enrollment in the TroFuse-019 (NCT06312137) Phase 3 clinical trial, designed for patients with resectable Non-Small Cell Lung Cancer (NSCLC) who did not achieve pathological Complete Response (pCR) after surgery. This trial aims to address a critical need for high-risk patients who undergo neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab (Keytruda) and chemotherapy, followed by surgery, but still have residual disease and a high risk of recurrence. Merck seeks to determine whether the combination of sacituzumab tirumotecan (MK-2870/SKB264), a TROP2-targeted Antibody-Drug Conjugate (ADC), with the Standard of Care (SOC) pembrolizumab adjuvant therapy can significantly extend Disease-Free Survival (DFS) in these patients.

Mechanism of Action of Combination Therapy

Sacituzumab tirumotecan, used in this trial, is a next-generation TROP2 ADC candidate that Merck licensed from Kelun-Biotech in May 2022 for an upfront payment of $47 million and potential milestone payments of up to $1.36 billion. This ADC selectively targets TROP2 protein, which is overexpressed on cancer cells, and delivers a cytotoxic payload, belotecan, directly into the tumor, inducing cancer cell death. The combination of pembrolizumab, which promotes an immune response, and an ADC that directly attacks the tumor, is considered an ideal combination to overcome the immunosuppressive Tumor Microenvironment (TME) and create synergistic effects, maximizing therapeutic efficacy.

Global Competitive Landscape

The global NSCLC treatment market is estimated at $20 billion to $30 billion in 2024, and competition is fierce for leadership in the perioperative treatment market, particularly for early-stage patients with high recurrence rates. In the TROP2 ADC market, Trodelvy from Gilead Sciences and Datopotamab deruxtecan (Dato-DXd), co-developed by AstraZeneca and Daiichi Sankyo, have already entered the commercial stage, posing a significant competitive challenge to Merck. Merck is at a critical juncture where it needs to establish its own ADC pipeline early and maintain its market share in response to the upcoming patent expiration of its blockbuster drug, Keytruda (expected in 2028).

Clinical Prospects and Value

If this Phase 3 clinical trial is successful and demonstrates improved DFS, Merck will be able to offer a new standard of care option for early-stage NSCLC patients and further solidify its market dominance. The lack of subsequent personalized treatment options for patients who do not achieve pCR after neoadjuvant pembrolizumab-based therapy (KEYNOTE-671, approved by the FDA on October 16, 2023) has been identified as a major unmet need, making this trial highly valuable. The results of this trial are expected to not only determine the success of Merck's oncology portfolio diversification but also set a new milestone that will reshape the next-generation ADC combination therapy market.